Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab

PHASE3TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 18, 2017

Primary Completion Date

September 12, 2018

Study Completion Date

September 12, 2018

Conditions
Relapsing-Remitting Multiple Sclerosis (RRMS)
Interventions
DRUG

Daclizumab

High yield formulation

Trial Locations (11)

14471

Research Site, Potsdam

20249

Research Site, Hamburg

33612

Research Site, Tampa

50314

Research Site, Des Moines

53501

Research Site, Milwaukee

80131

Research Site, Napoli

81675

Research Site, Munich

86077

Research Site, Pozzilli

T6G 2G3

Research Site, Edmonton

01307

Research Site, Dresden

00968

Research Site, Guaynabo

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Biogen

INDUSTRY